Leal is an AI-powered treatment decision support platform that provides personalized cancer treatment options by analyzing patient data and matching it with available therapies. The platform addresses the challenge of limited access to advanced cancer treatments by empowering patients to make informed decisions about their care.
Funding
$53.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer patients in rural areas often face significant barriers to accessing advanced genomic testing and personalized treatment options, leading to disparities in care and outcomes compared to patients in urban centers. Limited infrastructure, specialist availability, and awareness of cutting-edge therapies contribute to these disparities.
Solution
The Maine Cancer Genomics Initiative (MCGI) is a precision oncology program designed to reduce disparities in cancer care by providing community oncology practices with access to advanced genomic testing, clinical education, and clinical trial infrastructure. MCGI facilitates personalized treatment decisions by enabling comprehensive genomic profiling of patient tumors, which informs targeted therapy selection and clinical trial enrollment. The program offers educational resources for both clinicians and patients, enhancing understanding and adoption of precision medicine approaches. By partnering with oncology practices throughout Maine, MCGI ensures that patients in rural and underserved areas receive the same level of advanced cancer care as those in urban settings.
Target Audience
The primary audience includes oncology providers in community practices, cancer patients in rural Maine, and clinical researchers focused on precision oncology and cancer genomics.
Features
- Comprehensive genomic profiling of patient tumors to identify actionable mutations and guide treatment decisions
- Clinical trial matching services to connect patients with relevant research opportunities
- Genomic tumor boards to facilitate expert review and interpretation of complex genomic data
- Educational resources for clinicians on cancer genomics and precision medicine
- Patient advisory committee to ensure patient-centered care and address patient needs
- Telehealth support to expand access to genomic expertise and personalized treatment planning